Live Feeds
● LIVE Updated 1h ago · 27 sources tracked

Cure for certain cancers is ‘realistic’ goal in next decade, pharma lead says

Johnson & Johnson CEO Joaquin Duato expects some cancers to be curable in the next decade. He cites advancements in immunotherapy and multiple myeloma treatments. A collaboration between Merck and Moderna is testing a personalized mRNA vaccine combined with KEYTRUDA.

RSS Source map (26)

What changed

New data indicates a combined mRNA vaccine and immunotherapy treatment reduces melanoma recurrence over five years.

Live updates

  1. Pharma Lead Views Certain Cancer Cures as Realistic Within Ten Years

    Johnson & Johnson CEO Joaquin Duato expects some cancers to be curable in the next decade. He cites advancements in immunotherapy and multiple myeloma treatments. A collaboration between Merck and Moderna is testing a personalized mRNA vaccine combined with KEYTRUDA.

    What's confirmed:

    • Johnson & Johnson CEO Joaquin Duato believes curing some cancers is a realistic goal for the next decade.
    • A personalized mRNA vaccine paired with the drug KEYTRUDA is showing promising results for melanoma patients.
    • The Merck and Moderna collaboration developed an injectable treatment that reduces cancer recurrence over a five-year period.
    confidence 100%

  2. J&J CEO views certain cancer cures as realistic within 10 years

    Johnson & Johnson CEO Joaquin Duato believes curing some cancers is a realistic goal for the next decade. He points to immunotherapy breakthroughs and progress in multiple myeloma. New data shows a specific treatment is reducing death risks for myeloma patients.

    What's confirmed:

    • Johnson & Johnson CEO Joaquin Duato stated that curing certain cancers is a realistic goal in the next decade.
    • Duato cited immunotherapy and multiple myeloma progress as drivers for this goal.
    • Some multiple myeloma patients have been in remission for over five years due to immunotherapy breakthroughs.

    Still unconfirmed:

    • Phase 3 MonumenTAL-3 data showed TALVEY cuts myeloma death risk 53%.
    • Johnson & Johnson has a $1B bet on a preclinical KRAS protein degrader.
    confidence 90%

  3. J&J CEO Calls Cure for Certain Cancers a Realistic Goal Within Decade

    Johnson & Johnson CEO Joaquin Duato states that curing certain cancers in the next 10 years is a realistic goal. He cited progress in immunotherapy and multiple myeloma as key drivers. The company is prioritizing oncology and neuroscience over the obesity drug market.

    What's confirmed:

    • Johnson & Johnson CEO Joaquin Duato believes curing certain cancers within a decade is a realistic goal.
    • The company is avoiding the GLP-1 obesity medication space to focus on cancer treatments.
    • Duato cited immunotherapy and multiple myeloma progress as evidence of significant advances.
    • Joaquin Duato spoke about these goals at a CEO summit in London.
    • AI is assisting Johnson & Johnson in developing medicines more quickly.

    Still unconfirmed:

    • Johnson & Johnson agreed to acquire Firefly Bio for $1 billion.
    • The company aims to be the number one provider of cancer treatments by 2030.
    confidence 95%